Form 4: Medtronic CFO Thierry Pieton Reports Significant Equity Compensation Grants

Medtronic plc's Executive Vice President and Chief Financial Officer, Thierry Pieton, reported the acquisition of restricted stock units, performance share units, and stock options as part of his compensation.

Summary

• Thierry Pieton, Medtronic plc's EVP & Chief Financial Officer, reported the acquisition of various equity securities.
• Acquired 8,699 Ordinary Shares in the form of Restricted Stock Units (RSUs) at a price of $0, which will vest 100% on July 28, 2028.
• Acquired 21,747 Performance Share Units (PSUs) at a price of $0, with performance conditions expected to be satisfied by April 28, 2028.
• The number of shares issued for PSUs can range from 0 to 43,494, depending on performance metrics over a three-year period, with 21,747 shares issued if target metrics are achieved.
• Acquired 61,338 Stock Options (Right to Buy) with an exercise price of $91.97.
• These stock options become exercisable at a rate of 25% per year, starting on July 28, 2026, and expire on July 28, 2035.
• Beneficial ownership of non-derivative Ordinary Shares following these transactions is 39,958, which includes 505 shares acquired through dividend reinvestment since the last report.

Sentiment

Score: 7

Explanation: The filing indicates a positive alignment of executive interests with shareholder value through equity compensation, which is a standard and generally well-regarded practice.

Positives

• The grants of Restricted Stock Units, Performance Share Units, and Stock Options align the interests of the Chief Financial Officer with those of the shareholders.
• Equity compensation is a standard practice for retaining and incentivizing key executives.

Future Outlook

The filing details future vesting schedules for Restricted Stock Units (July 28, 2028), performance condition satisfaction for Performance Share Units (April 28, 2028), and the exercisability schedule for Stock Options (25% annually starting July 28, 2026, expiring July 28, 2035).

Industry Context

This filing represents a routine executive compensation grant, common across publicly traded companies in the medical technology and broader healthcare industry, aimed at aligning executive incentives with long-term shareholder value.

Stakeholder Impact

• Shareholders: The equity grants align the CFO's financial interests with the company's long-term performance, potentially benefiting shareholders through improved executive motivation and strategic decisions.

Next Steps

• Vesting of Restricted Stock Units on July 28, 2028.
• Satisfaction of performance conditions for Performance Share Units by April 28, 2028, leading to potential share issuance.
• Stock options becoming exercisable annually at 25% starting July 28, 2026.

Key Dates

Keywords

Medtronic, MDT, SEC Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Performance Share Units, Stock Options, Thierry Pieton